FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3170189973> ?p ?o ?g. }

• W3170189973 endingPage "2836" @default.
• W3170189973 startingPage "2836" @default.
• W3170189973 abstract "Due to the limited effectiveness of immunotherapy used as first-line monotherapy in patients with non-small-cell lung cancer (NSCLC), the concepts of combining classical immunotherapy based on immune checkpoint antibodies with other treatment methods have been developed. Pembrolizumab and atezolizumab were registered in combination with chemotherapy for the treatment of metastatic NSCLC, while durvalumab found its application in consolidation therapy after successful chemoradiotherapy in patients with locally advanced NSCLC. Exceptionally attractive, due to their relatively low toxicity and high effectiveness, are treatment approaches in which a combination of two different immunotherapy methods is applied. This method is based on observations from clinical trials in which nivolumab and ipilimumab were used as first-line therapy for advanced NSCLC. It turned out that the dual blockade of immune checkpoints activated T lymphocytes in different compartments of the immune response, at the same time affecting the downregulation of immune suppressor cells (regulatory T cells). These experiments not only resulted in the registration of combination therapy with nivolumab and ipilimumab, but also initiated other clinical trials using immune checkpoint inhibitors (ICIs) in combination with other ICIs or activators of costimulatory molecules found on immune cells. There are also studies in which ICIs are associated with molecules that modify the tumour environment. This paper describes the mechanism of the synergistic effect of a combination of different immunotherapy methods in NSCLC patients." @default.
• W3170189973 created "2021-06-22" @default.
• W3170189973 creator A5023250116 @default.
• W3170189973 creator A5045938961 @default.
• W3170189973 creator A5051885027 @default.
• W3170189973 creator A5061273516 @default.
• W3170189973 date "2021-06-07" @default.
• W3170189973 modified "2023-09-27" @default.
• W3170189973 title "Two Complementarity Immunotherapeutics in Non-Small-Cell Lung Cancer Patients—Mechanism of Action and Future Concepts" @default.
• W3170189973 cites W1487731794 @default.
• W3170189973 cites W1849671624 @default.
• W3170189973 cites W1921303390 @default.
• W3170189973 cites W1987165863 @default.
• W3170189973 cites W2029399624 @default.
• W3170189973 cites W2037610638 @default.
• W3170189973 cites W2066671159 @default.
• W3170189973 cites W2070443202 @default.
• W3170189973 cites W2107746773 @default.
• W3170189973 cites W2112601576 @default.
• W3170189973 cites W2130473166 @default.
• W3170189973 cites W2136399042 @default.
• W3170189973 cites W2137704240 @default.
• W3170189973 cites W2140875987 @default.
• W3170189973 cites W2142169541 @default.
• W3170189973 cites W2157041114 @default.
• W3170189973 cites W2161261138 @default.
• W3170189973 cites W2166662937 @default.
• W3170189973 cites W2175045656 @default.
• W3170189973 cites W2276790712 @default.
• W3170189973 cites W2293531514 @default.
• W3170189973 cites W2299327880 @default.
• W3170189973 cites W2395714980 @default.
• W3170189973 cites W2403400382 @default.
• W3170189973 cites W2460289592 @default.
• W3170189973 cites W2518412322 @default.
• W3170189973 cites W2554978154 @default.
• W3170189973 cites W2592133876 @default.
• W3170189973 cites W2742763599 @default.
• W3170189973 cites W2765132620 @default.
• W3170189973 cites W2767273350 @default.
• W3170189973 cites W2767441088 @default.
• W3170189973 cites W2775687989 @default.
• W3170189973 cites W2781947653 @default.
• W3170189973 cites W2786095824 @default.
• W3170189973 cites W2790270315 @default.
• W3170189973 cites W2794125175 @default.
• W3170189973 cites W2794612508 @default.
• W3170189973 cites W2795455773 @default.
• W3170189973 cites W2796643083 @default.
• W3170189973 cites W2805354595 @default.
• W3170189973 cites W2809650769 @default.
• W3170189973 cites W2810896552 @default.
• W3170189973 cites W2887577080 @default.
• W3170189973 cites W2889169377 @default.
• W3170189973 cites W2891215230 @default.
• W3170189973 cites W2891251479 @default.
• W3170189973 cites W2899358783 @default.
• W3170189973 cites W2901255808 @default.
• W3170189973 cites W2910245285 @default.
• W3170189973 cites W2912137016 @default.
• W3170189973 cites W2925446385 @default.
• W3170189973 cites W2940591955 @default.
• W3170189973 cites W2940611353 @default.
• W3170189973 cites W2947747173 @default.
• W3170189973 cites W2949515538 @default.
• W3170189973 cites W2975608733 @default.
• W3170189973 cites W2976744492 @default.
• W3170189973 cites W2981443129 @default.
• W3170189973 cites W2982230829 @default.
• W3170189973 cites W2985170860 @default.
• W3170189973 cites W2987385271 @default.
• W3170189973 cites W3003803477 @default.
• W3170189973 cites W3005425311 @default.
• W3170189973 cites W3010619270 @default.
• W3170189973 cites W3010808413 @default.
• W3170189973 cites W3011095436 @default.
• W3170189973 cites W3012474872 @default.
• W3170189973 cites W3021577750 @default.
• W3170189973 cites W3028301539 @default.
• W3170189973 cites W3029462827 @default.
• W3170189973 cites W3029572589 @default.
• W3170189973 cites W3031115858 @default.
• W3170189973 cites W3033538054 @default.
• W3170189973 cites W3036371943 @default.
• W3170189973 cites W3036376773 @default.
• W3170189973 cites W3040585898 @default.
• W3170189973 cites W3045601680 @default.
• W3170189973 cites W3046910142 @default.
• W3170189973 cites W3048361646 @default.
• W3170189973 cites W3084411570 @default.
• W3170189973 cites W3110576599 @default.
• W3170189973 cites W3114685627 @default.
• W3170189973 cites W3116374128 @default.
• W3170189973 cites W3119553910 @default.
• W3170189973 cites W3119664087 @default.
• W3170189973 cites W3121907365 @default.
• W3170189973 cites W3124587416 @default.
• W3170189973 cites W4239710358 @default.

• next